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Key messages
What is already known about this subject?
 ► Inactivated influenza vaccine is recommended 
in patients with autoimmune rheumatic 
diseases to minimise the increased risk 
of influenza and its complications in this 
population.
 ► Concerns about influenza vaccine associating 
with increased risk of autoimmune rheumatic 
disease (AIRD) activity and anecdotal reports of 
the influenza vaccine triggering diseases such 
as vasculitis are barriers to seasonal influenza 
vaccination.
What does this study add?
 ► Seasonal influenza vaccination is not associated 
with AIRD flare and vasculitis.
How might this impact on clinical practice or 
future developments?
 ► This study provides new data on the safety 
of influenza vaccine in people with AIRDs 
and adds to the accumulating evidence to 
support seasonal influenza vaccination in this 
population.
Objectives To examine the association between 
inactivated influenza vaccine (iiV) administration and 
primary care consultation for joint pain, rheumatoid 
arthritis (Ra) flare, corticosteroid prescription, vasculitis 
and unexplained fever in people with autoimmune 
rheumatic diseases (aiRds).
Methods We undertook within-person comparisons 
using self-controlled case-series methodology. aiRd 
cases who received the iiV and had an outcome of 
interest in the same influenza cycle were ascertained 
in clinical practice Research datalink. The influenza 
cycle was partitioned into exposure periods (1–14 days 
prevaccination and 0–14, 15–30, 31–60 and 61–90 
days postvaccination), with the remaining time-period 
classified as non-exposed. incidence rate ratios (iRR) and 
95% ci for different outcomes were calculated.
Results data for 14 928 aiRd cases (69% women, 
80% with Ra) were included. There was no evidence 
for association between vaccination and primary care 
consultation for Ra flare, corticosteroid prescription, fever 
or vasculitis. on the contrary, vaccination associated with 
reduced primary care consultation for joint pain in the 
subsequent 90 days (iRR 0.91 (95% ci 0.87 to 0.94)).
Conclusion This study found no evidence for a 
significant association between vaccination and primary 
care consultation for most surrogates of increased 
disease activity or vaccine adverse-effects in people with 
aiRds. it adds to the accumulating evidence to support 
influenza vaccination in aiRds.
InTROduCTIOn
Autoimmune rheumatic diseases (AIRDs) such as 
rheumatoid arthritis (RA) associate with increased 
risk of influenza and its complications.1 Even 
though inactivated influenza vaccine (IIV) has 
clinical and serological effectiveness in AIRDs, its 
uptake remains suboptimal.2–4 For instance, when 
AIRDs were the sole indication for vaccination, 
49% and 59% people aged 18–44 and 45–64 years, 
respectively, were vaccinated in the 2015–2016 
influenza season in the UK,5 with lower vaccine 
uptake reported in Germany.6
Barriers to IIV include scepticism about effec-
tiveness, concerns about side effects or disease flare 
and reports of vaccination triggering AIRDs such as 
vasculitis.7–11 Trials assessing serological response to 
IIV report stable disease activity following vaccina-
tion provided disease-modifying antirheumatic drugs 
(DMARDs) treatment is continued.12 13 However, 
these studies typically include people with stable 
disease, and, to the best of our knowledge, a real-
world study evaluating the effect of IIV on AIRDs 
has not been performed. Thus, the objectives of this 
study were to investigate the association between IIV 
administration and primary care consultation for 
joint pain, RA flare, new oral corticosteroid prescrip-
tion and potential vaccine adverse effects, such as 
vasculitis and non-infective fever.
MeTHOds
data source
Data were extracted from the Clinical Practice 
Research Datalink (CPRD).14 CPRD is a longitu-
dinal database of anonymised health records of 
>15 million people registered in >700 general 
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Figure 1 Influenza cycle divided into baseline, prevaccination and postvaccination periods. The baseline extended from latest of diagnosis date 
or 1st September in index year to 15 days pre-vaccination,and from 90 days post-vaccination to earliest of 31st August of the next year, date of 
leaving GP surgery, date of death, or latest date of data collection. Exposed period extended from vaccination to 90 days later,and was categorised as 
illustrated above.
practices in the UK. Participants are representative of the UK 
population.14 It contains details of demographics, diagnoses, 
immunisations, prescriptions and lifestyle factors.
study design
Self-controlled case series (SCCS) was developed for assessing 
associations between exposures and outcomes using data from 
participants who develop an outcome of interest and is an 
accepted methodology for vaccine safety studies.15 16 It has the 
advantage of being unaffected by between-person confounding 
as each participant acts as their own control. However, it does 
not account for time varying covariates such as season which 
vary between the unexposed and exposed periods.
source population
Adults aged ≥18 years with RA, spondyloarthritis (SpA) or 
systemic lupus erythematosus (SLE) and prescribed DMARDs.3
study period
The study period was 1 September 2006 to 31 of August 2016. 
This was partitioned into 10 influenza cycles, beginning on 1 
September of 1 year and ending on 31 August the subsequent 
year. Due to the use of non-standard monovalent vaccine along-
side trivalent IIV during 2009–2010 pandemic year, data for 
this year were excluded. Observation periods for each year were 
censored if death, emigration from general practice or last collec-
tion of data from general practice occurred before 31 August of 
the subsequent year.
exposure and outcomes
Vaccination, the exposure of interest, was defined using Read 
codes5 and event dates. Influenza cycles in which a patient was 
coded as having received the IIV elsewhere, for example, at work 
for health care professionals or in community pharmacies were 
excluded from the analysis as the date of vaccination outside 
primary care is not recorded in the CPRD. For cases with >1 
entry for vaccination in an influenza cycle, the earliest record 
was retained.
The outcomes were primary care consultation for:
A. Surrogates of disease activity: joint pain, flare of RA and new 
corticosteroid prescriptions.
B. Vaccine hypersensitivity: vasculitis, non-infective fever. Only 
the first Read code for vasculitis was considered since it is 
a chronic illness, and, participants diagnosed with vasculitis 
before study entry were excluded.
See online supplementary material for details.
exposure and unexposed periods
The influenza cycle was divided into unexposed and exposed 
periods, and the latter was further categorised into smaller time 
periods (figure 1). The first cut-off was selected at 14-day post-
vaccination as it takes 2 weeks for the IIV to induce a serolog-
ical response, and, we hypothesised that this period of immune 
reconstitution was most likely to associate with disease activity.17 
The 14-day period immediately preceding vaccination was 
excluded from the baseline period to minimise confounding due 
to healthy vaccinee effect.18
statistical analyses
SCCS involves fitting a Poisson model conditioned on the number 
of events and calculates incidence rate ratios and 95% CI for each 
exposure period. Distinct SCCS analysis data sets were drawn 
for each outcome. Each participant contributed data from one 
randomly selected eligible influenza cycle in which both vaccina-
tion and an outcome of interest occurred (online supplementary 
table S1). We analysed data from single randomly selected influ-
enza cycle since people who develop an adverse outcome tempo-
rally closely related to vaccination, for example, joint pain within 
1–2 weeks of vaccination, will be less likely to attend for repeat 
vaccinations compared to those who have such an event after a 
longer time period. Thus, if vaccination was to cause an adverse 
effect, including data from all influenza cycles in which an outcome 
occurred for a study participant would introduce differential bias. 
Except for vasculitis, >1 event of the same type in an influenza 
cycle were considered as recurrent episodes provided the interval 
between any two consultations was ≥15 days.
As corticosteroids are prescribed for many reasons, we 
performed sensitivity analysis restricted to corticosteroid 
prescription on the same day on which there is a primary care 
consultation for joint pain or RA flare. All analyses were carried 
out using Stata V.14.
ResulTs
Data for 14 928 AIRD cases with ≥1 outcome of interest in an 
influenza cycle in which they received the IIV were included. Of 
these, 11 953 (80.07%) had RA, 2347 (15.72%) had SpA and 
628 (4.21%) had SLE. The majority were female (68.5%) and 
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Table 1 Association between IIV and consultation for joint pain, new corticosteroid prescription and RA flare
Outcome Risk period events (n) Person-time (days) IRR (95% CI)* P value*
Joint pain
  
Unexposed 9977 2 712 373 1.00 <0.001
15 days prevaccination 788 160 775 1.29 (1.20 to 1.39)
Postvaccination intervals 
0–14 days 479 150 314 0.84 (0.77 to 0.92) <0.001
15–30 days 567 160 842 0.94 (0.86 to 1.02) 0.127
31–60 days 1121 321 024 0.93 (0.88 to 0.99) 0.025
61–90 days 1069 319 890 0.90 (0.84 to 0.96) 0.001
Corticosteroid
prescription
  
  
Unexposed 9470 2 266 070 1.00 <0.001 
15 days prevaccination 704 135 493 1.21 (1.12 to 1.31)
Postvaccination intervals 
0–14 days 539 126 625 1.00 (0.91 to 1.09) 0.924
15–30 days 554 135 515 0.96 (0.88 to 1.04) 0.338
31–60 days 1151 270 109 1.00 (0.95 to 1.07) 0.876
61–90 days 1182 268 968 1.04 (0.98 to 1.11) 0.184
RA flare
  
  
Unexposed 460 153 247 1.00 0.785 
15 days prevaccination 24 8957 0.95 (0.64 to 1.41)
Postvaccination intervals 
0–14 days 27 8400 0.97 (0.65 to 1.45) 0.888
15–30 days 29 9000 1.12 (0.78 to 1.62 0.525
31–60 days 59 18 000 1.06 (0.80 to 1.39) 0.693
61–90 days 46 17 978 0.81 (0.59 to 1.10) 0.180
*Statistically significant results are in bold (p<0.05).
IIV, inactivated influenza vaccine; IRR, incidence rate ratio; RA, rheumatoid arthritis.
Table 2 Association between inactivated influenza vaccine, vasculitis and unexplained fever*
Outcome Risk period events (n) Person-time (days) Incidence rate ratio (95% CI) P values
Vasculitis
  
Unexposed 89 30 936 1.00 0.906
15 days prevaccination 5 1815 0.95 (0.38 to 2.33)
Postvaccination intervals
  
0–14 days X1 1694 0.41 (0.10 to 1.65) 0.207
15–30 days 5 1815 0.95 (0.38 to 2.33) 0.906
31–60 days 8 3630 0.76 (0.37 to 1.56) 0.453
61–90 days 12 3630 1.14 (0.62 to 2.08) 0.677
Unexplained Unexposed 92 30 735 1.00 0.507 
Fever
  
15 days prevaccination X1 1819 0.71 (0.26 to 1.94)
Postvaccination intervals
  
0–14 days X1 1708 0.71 (0.26 to 1.94) 0.589
15–30 days 6 1830 1.06 (0.28 to 2.07) 0.887
31–60 days 5 3650 0.45 (0.18 to 1.10) 0.079
61–90 days 12 3630 1.09 (0.60 to 1.99) 0.780
X1 fewer than five events in each cell, data suppressed according to Clinical Practice Research Datalink policy.
*Unexplained fever was defined as fever not due to a known cause, for example, infection.
their mean (SD) age was 59 (14) years. Vaccination associated 
with fewer primary care consultations for joint pain with the 
magnitude of reduction broadly consistent across the four risk 
periods (table 1). When data for the first 30 days were pooled 
together, vaccination associated with fewer primary care consul-
tations for joint pain (IRR 0.89 (95% CI 0.84 to 0.9)). The 
14-day prevaccination period associated with significantly more 
primary care consultations for joint pain and new corticosteroid 
prescriptions (table 1). The median (IQR) corticosteroid dose 
was 10 (5–30) mg/day prednisolone equivalents, data available 
for 54% prescriptions.
There were no significant associations between vaccination 
and other adverse outcomes in this study (tables 1 and 2). On 
sensitivity analysis, vaccination was not associated with new 
corticosteroid prescription on the same day on which there was 
a primary care consultation for either RA flare or joint pain 
(online supplementary table S2).
dIsCussIOn
This study reports no significant associations between 
IIV administration and new primary-care corticosteroid 
prescriptions or primary care consultations for vasculitis and 
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non-infective fever. However, there was a negative association 
between vaccination and primary care consultations for joint 
pain upto 90 days postvaccination. Further research is required 
to understand the underlying mechanism. It is unlikely to result 
from contextual response or healthy vaccine effect as there is 
no prevalent belief that vaccination improves AIRD outcomes, 
and SCCS utilises within-person comparisons accounting for 
the latter. However, this observation could result from regres-
sion to the mean.
We observed increased primary care consultation for joint pain 
and new corticosteroid prescriptions in the 14 days preceding 
vaccination. This could indicate opportunistic vaccine promo-
tion to people consulting for AIRD flare. Alternatively, this may 
be due to the fact that most influenza vaccinations occur in late 
autumn and winter months5 that coincide with increased AIRD 
activity. It is therefore of interest that the 30-day postvaccination 
period, also in the late autumn and winter months, expected to 
have more consultations for joint pain, had significantly fewer 
consultations.
The potential for vaccines to elicit an immune-mediated 
adverse reaction has raised concerns about a link between 
vaccines and AIRDs.9 10 However, our data do not identify a 
significant association between vaccination and vasculitis and are 
in line with other studies.19 Similarly, there was no association 
between IIV and incident RA in the Epidemiological Investiga-
tion of Rheumatoid Arthritis cohort.20
The main strength of this study is its robust design, employing 
the SCCS method. By performing within-person comparisons, 
it minimises the influence of confounding between individuals, 
a serious problem in observational studies of adverse-effects 
following vaccination. Additionally, the use of consultation and 
prescription data minimised recall bias. The inclusion of a broad 
spectrum of AIRDs makes our findings generalisable. Addition-
ally, we performed sensitivity analysis restricting to corticoste-
roid prescriptions on the same day as primary care consultation 
for either joint pain or RA flare.
However, there are several limitations to this study. First, 
data on disease activity is not recorded in the CPRD, and 
primary care consultations occur at least a few days after flare 
onset. Self-managed flares and those managed by rheumatol-
ogists are excluded. Thus, the use of consultation-based data-
base underestimates the event rate. However, these caveats are 
unlikely to affect the validity of our findings as there is no 
reason for the ratio between events and primary care consulta-
tions to vary across the influenza-cycle. Our a priori decision 
to restrict the data analysis to one randomly selected influ-
enza-cycle may have reduced the power for some outcomes 
such as new corticosteroid prescription which occurred in ≥2 
influenza cycles for 50% participants. This does not apply to 
other uncommon outcomes, about 90% of which occurred in 
only one influenza cycle.
In conclusion, this study supports the safety of influenza 
vaccine in AIRDs. These data should be used to address the fear 
of adverse effects from vaccination, an important reason for 
suboptimal uptake of influenza vaccination in AIRDs.
Contributors aa conceived the idea for the study and all authors planned the 
study collaboratively. aa, mg and gn developed the analysis plan; data analysis 
was undertaken by gn and supervised by mg and aa. Jsn-V-T and pRm provided 
influenza specific input and advised on the data analysis plan. cdm provided primary 
care input. aa together with gn wrote the first draft of the manuscript. all authors 
reviewed the results and critically reviewed the manuscript for intellectual content. 
all authors approved the final version of the manuscript.
Funding This work was supported by Versus arthritis (grant number 21297), 
formerly arthritis Research UK, and the national institute of Health Research (niHR-
Rp-2014-04-026).
Competing interests cdm is funded by the national institute for Health Research 
(niHR) collaborations for leadership in applied Health Research and care West 
midlands, the niHR school for primary care Research and an niHR Research 
professorship in general practice (niHR-Rp-2014-04-026). Jsn-V-T acknowledges 
funding from the niHR Biomedical Research centre (acute respiratory infections), 
md and aa acknowledge funding from the niHR Biomedical Research centre 
(musculoskeletal theme) nottingham. potential conflicts of interest: Jsn-V-T is 
currently on secondment to the department of Health and social care, England 
(dHsc). The views expressed in this paper are those of the authors and do not 
necessarily represent those of the national Health service, niHR or dHsc. all other 
authors have declared no conflicts of interest.
Patient consent for publication not required.
ethics approval The study was approved by the independent scientific advisory 
committee (Reference: 16_288R).
Provenance and peer review not commissioned; externally peer reviewed.
data sharing statement data may be obtained from a third party and are not 
publicly available.
Open access This is an open access article distributed in accordance with the 
creative commons attribution 4.0 Unported (cc BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. see: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
RefeRences
 1 Blumentals Wa, arreglado a, napalkov p, et al. Rheumatoid arthritis and the incidence 
of influenza and influenza-related complications: a retrospective cohort study. BMC 
Musculoskelet Disord 2012;13.
 2 chen c-m, chen H-J, chen W-s, et al. clinical effectiveness of influenza vaccination 
in patients with rheumatoid arthritis. Int J Rheum Dis 
 2018;21:1246–53.
 3 nakafero g, grainge mJ, myles p, et al. inactivated influenza vaccine prevents 
respiratory infections and improves all-cause and cause-specific mortality in 
immunosuppressed people with autoimmune rheumatic diseases: propensity score 
adjusted cohort study using data from clinical practice Research datalink. Arthritis & 
Rheumatology 2018;70:1–3584.
 4 Hua c, Barnetche T, combe B, et al. Effect of methotrexate, anti-tumor necrosis factor 
α, and rituximab on the immune response to influenza and pneumococcal vaccines 
in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis 
Care Res 2014;66:1016–26.
 5 nakafero g, grainge mJ, myles pR, et al. predictors and temporal trend of flu 
vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective 
cohort study. Rheumatology 2018;57:1726–34.
 6 luque Ramos a, Hoffmann F, callhoff J, et al. influenza and pneumococcal 
vaccination in patients with rheumatoid arthritis in comparison with age- 
and sex-matched controls: results of a claims data analysis. Rheumatol Int 
2016;36:1255–63.
 7 loubet p, Kernéis s, groh m, et al. attitude, knowledge and factors associated with 
influenza and pneumococcal vaccine uptake in a large cohort of patients with 
secondary immune deficiency. Vaccine 2015;33:3703–8.
 8 Bridges mJ, coady d, Kelly ca, et al. Factors influencing uptake of influenza 
vaccination in patients with rheumatoid arthritis.  
Ann Rheum Dis 2003;62:685.
 9 iyngkaran pet al. Rheumatoid vasculitis following influenza vaccination. 
Rheumatology 2003;42:907–9.
 10 Birck R, Kaelsch i, schnuelle p, et al. anca-associated vasculitis following 
influenza vaccination: causal association or mere coincidence? J Clin Rheumatol 
2009;15:289–91.
 11 Kirchner E, Ruffing V. Barriers to immunizations and strategies to enhance 
immunization rates in adults with autoimmune inflammatory diseases. Rheumatic 
Disease Clinics of North America 2017;43:15–26.
 12 park JK, lee YJ, shin K, et al. impact of temporary methotrexate discontinuation 
for 2 weeks on immunogenicity of seasonal influenza vaccination in patients 
with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 
2018;77:898–904.
 13 park JK, lee ma, lee EY, et al. Effect of methotrexate discontinuation on efficacy of 
seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised 
clinical trial. Ann Rheum Dis 2017;76:1559–65.
 14 Herrett E, gallagher am, Bhaskaran K, et al. data resource profile: clinical practice 
Research datalink (cpRd). Int J Epidemiol 2015;44:827–36.
 15 Whitaker HJ, Farrington cp, spiessens B, et al. Tutorial in biostatistics: the self-
controlled case series method. Stat Med 2006;25:1768–97.
 16 smeeth l, Thomas sl, Hall aJ, et al. Risk of myocardial infarction and stroke after 
acute infection or vaccination. N Engl J Med 2004;351:2611–8.
1126 Nakafero G, et al. Ann Rheum Dis 2019;78:1122–1126. doi:10.1136/annrheumdis-2019-215086
Miscellaneous
 17 gross pa, Russo c, dran s, et al. Time to earliest peak serum antibody response to 
influenza vaccine in the elderly. Clin Diagn Lab Immunol 1997;4:491–2.
 18 shrank WH, patrick aR, Brookhart ma. Healthy user and related biases in 
observational studies of preventive interventions: a primer for physicians. J Gen Intern 
Med 2011;26:546–50.
 19 Watanabe T. Vasculitis following influenza vaccination: a review of the literature. Curr 
Rheumatol Rev 2017;13:188–96.
 20 Bengtsson c, Kapetanovic mc, Källberg H, et al. common vaccinations among adults 
do not increase the risk of developing rheumatoid arthritis: results from the swedish 
EiRa study. Ann Rheum Dis 2010;69:1831–3.
